SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Cell Therapeutics (CTIC)
An SI Board Since August 1997
Posts SubjectMarks Bans Symbol
946 45 0 CTIC
Emcee:  Regis McConnell Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
721Cell Therapeutics CEO still in place after board vote. Bianco dissidents questioIcebrg-8/23/2005
720Seeing Link and Spinelli resign from the board and Spinelli also from the companIcebrg-8/23/2005
719I gather there was some language in the 10-Q to the effect that recent discussiotuck-8/23/2005
718There could be a coattail effect from today’s Newsweek cover story on lung canceDewDiligence_on_SI-8/15/2005
71710Q: In March 2005, we announced that while the STELLAR 3 study missed its primaMao II-8/11/2005
716Bailing out at CTIC. Of course without Trisenox, what's to market? <i>keokalani'nui-8/3/2005
715At least with Stellar 3 and 4 you are looking at PS2 in front-line therapy. Addgcrispin-7/10/2005
714Perhaps, but a helpful one. <G> <i>Your friendly neighborhood statiIan@SI-7/6/2005
713<i>In addition, in the first-line STELLAR 3 and 4 trials in poor performanClarksterh-7/6/2005
712Unfortunately, if a company backs into treating a subset, it will still have theIan@SI-7/6/2005
711Well, I must say, if the whole advance towards personalized medicine is going totuck-7/6/2005
710Maybe he didn't like this PR... There were a couple good points in it. IaIan@SI-7/6/2005
709It was shares although not yet available to him. They were granted in February, Icebrg-7/6/2005
708Sounds as though he surrendered unexercised options, if that is consistent with quidditch-7/6/2005
707Aselage, the marketing director who left to join BioMarin, has filed a form 4, rIcebrg-7/6/2005
706Item 1.01. Entry into a Material Definitive Agreement. Severance Agreement On Icebrg-6/30/2005
705Yes, I saw that. It seems he really believed in Xyotax. Maybe, he still does. EIcebrg-6/28/2005
704Anybody notice that Bianco had to cough up some shares due to a margin call? I gtuck-6/28/2005
703As It Focuses On Xyotax, CTI Selling Trisenox To Cephalon [Some comments from BIcebrg-6/23/2005
702Evidently they (or maybe he) have written off any chance of getting Xyotax to thIcebrg-6/21/2005
701I guess with trisenox finally gone, a company doesn't need some of the high Ian@SI-6/21/2005
700NOVATO, Calif., June 21 /PRNewswire-FirstCall/ -- BioMarin Pharmaceutical Inc. (Icebrg-6/21/2005
699I haven't seen anything recently. Bianco still seems focussed on Xyotax.Ian@SI-6/20/2005
698Anybody remember what CTIC's strategy for commercializing Pix is? Has it betuck-6/20/2005
697CTIC also has 195 million in debt. I believe that the company will be bought ogcrispin-6/16/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News